SCHEMBL6475469

SCHEMBL6475469

CCCS(=O)(=O)NCC(C)Oc1ccc(-c2cccc(C(F)(F)F)c2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 2/20 0.43
PLAT P00750 2/20 0.43
ADAMTS4 O75173 2/20 0.41
MMP13 P45452 2/20 0.41
GRIA4 P48058 1/20 0.40
GRIA2 P42262 1/20 0.40
KCNH2 Q12809 1/20 0.40
ALDH1A1 P00352 1/20 0.39
HSD17B10 Q99714 1/20 0.39
ADAMTS5 Q9UNA0 1/20 0.39
PLG P00747 1/20 0.39
SIGMAR1 Q99720 1/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
ADRA2C P18825 1/20 0.39
HTR2A P28223 1/20 0.39
SLC6A4 P31645 1/20 0.39
ADRA1A P35348 1/20 0.39
DRD3 P35462 1/20 0.39
OPRK1 P41145 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6474227 0.89 KIF11 (0.46) ADAMTS4MMP13GRIA4KCNH2ALDH1A1
SCHEMBL6479543 0.86 GRIA4 (0.45) ADAMTS4MMP13GRIA4MAPTGPR34
SCHEMBL6475465 0.86 GRIA2 (0.48) PLAUPLATADAMTS4MMP13GRIA4
SCHEMBL6474047 0.84 PPARG (0.44) MMP13GRIA4ALDH1A1MAPT
SCHEMBL6475297 0.84 GRIA4 (0.48) MMP13GRIA4ALDH1A1MAPTCYP1A2
SCHEMBL6482324 0.84 GRIA4 (0.46) MMP13GRIA4HSD17B10MAPTCYP1A2
SCHEMBL6474263 0.84 GRIA4 (0.40) ADAMTS4MMP13GRIA4ALDH1A1
SCHEMBL6474430 0.84 PLAU (0.40) PLAUGRIA4MAPT
SCHEMBL6474219 0.84 MTNR1A (0.50) PLAUGRIA4HSD17B10MAOB
SCHEMBL6481819 0.83 SMN1; SMN2 (0.44) GRIA4GRIA2ADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6911476-B2 Sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-06-28 US claimed
EP-1265857-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-12-18 EP claimed
WO-2001068592-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2001-09-20 WO claimed
US-6911476-B2 Sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-06-28 US disclosed
US-20030225266-A1 Sulfonamide derivatives ELI LILLY AND COMPANY 2003-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225266-A1 Sulfonamide derivatives GRIN2A, GRM2, GRIA2 PLAU 4010/4885PLAT 4741/4885ADAMTS4 3755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.